SNMMI Elects Richard L. Wahl, MD, as Vice President-Elect During 2019 Annual Meeting

June 24, 2019

Anaheim, California — Richard L. Wahl, MD, has been elected as 2019-20 vice president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Wahl is the Elizabeth E. Mallinckrodt Professor and head of radiology at Washington University School of Medicine in St. Louis, director of the university’s Mallinckrodt Institute of Radiology and a professor of radiation oncology. SNMMI introduced a new slate of officers during its 2019 Annual Meeting, June 22–25 in Anaheim, California.


“Nuclear medicine is undergoing a renaissance as a precision medicine specialty with new radiopharmaceuticals, theranostics, and instrumentation to elucidate biology and benefit patients,” Wahl stated. In his years in office, he plans to focus on advocacy for nuclear medicine, enhancing the number of professionals working in nuclear medicine, and discovery and innovation. He also plans to work to ensure patients have access to modern nuclear medicine diagnostic and therapeutic procedures.

After graduating from Washington University School of Medicine and serving his residency there, Wahl interned at the University of California at San Diego School of Medicine. He returned to Washington University in 1979 for training in diagnostic radiology and nuclear medicine. He accepted his first faculty appointment at the University of Michigan in 1983. From there, Wahl moved to Johns Hopkins University, where he was the Henry N. Wagner Jr., MD, professor and director of the Division of Nuclear Medicine; vice chair for technology and new business development in the Russell H. Morgan Department of Radiology and Radiological Sciences; and a professor of oncology. He accepted his current appointment at Washington University in 2014.

A longtime SNMMI member, Wahl currently serves as the chair of the Research and Discovery domain for the society’s Value Initiative. He has served on the editorial board of The Journal of Nuclear Medicine for many years. He is a member of several councils and centers of excellence at the society, as well as the Missouri Valley Chapter. He is a life member of the American Board of Nuclear Medicine, having served as chairman of the board. He also served as president of the Institute for Clinical PET.

Wahl is an elected member of the National Academy of Medicine and has received honors from multiple organizations. He holds 18 patents and has published more than 450 peer-reviewed scientific manuscripts. He is the primary author of several textbooks, including Principles and Practice of PET and PET/CT. He has a strong interest in quantitative imaging, is on the coordinating committee of the Quantitative Imaging Biomarkers Alliance (QIBA) efforts of the Radiological Society of North America and has been a lead investigator in the Quantitative Imaging Network (QIN) of the National Institutes of Health.

His awards include a U.S. Department of Energy Achievement Award; the de Hevesy, Tetalman, Berson and Yalow and two Alavi-Mandel awards from SNMMI; and the Academy of Molecular Imaging’s Distinguished Scientist Award. He also was named the “Most Influential Radiology Researcher” in 2005 by, a leading website for medical imaging professionals. He has given many named lectureships throughout the world, including the Prendergas New Horizons Lecture at the Radiological Society of North America annual meeting and the Marie Curie Lecture at the European Association of Nuclear Medicine.

Other SNMMI officers elected for 2019-20 are Vasken Dilsizian, MD, Baltimore, Maryland, as president and Alan Packard, PhD, Boston, Massachusetts, as president-elect. SNMMI Technologist Section officers for 2019-20 are Mark H. Crosthwaite, MEd, CNMT, PET, FSNMMI-TS, Richmond, Virginia, as president and Tina M. Buehner, MS, CNMT, NMTCB(CT)(RS), RT(N)(CT), FSNMMI-TS, Chicago, Illinois, as president-elect.


About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI’s more than 16,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit